Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Clinical Trials in Fullerton, California

Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy